Gastric cancer is the third greatest cause of cancer deaths globally, after only lung and colorectal cancer in overall mortality, according to GLOBOCAN 2018 data. Gastric cancer is responsible for about 1 in every 12 oncological fatalities. Gastric cancer is the sixth highest incidence rate, accounting for 5.7 percent of all new cases. Every year, about a million new instances of stomach cancer are diagnosed worldwide. Thus, the rising incidence of cancers across the globe is expected to accelerate the demand for gastric cancer diagnostics, thus, the increased incidence rates of gastrointestinal tumors, lymphoma, and adenocarcinoma is boosting the growth of the market.
Data Bridge Market Research analyses that the gastric cancer diagnostics market is expected to grow at a CAGR of 6.8% in the forecast period of 2022 to 2029 and is expected to reach USD 1,597.69 million by 2029. Also, with this increasing age and rising prevalence of chronic diseases, the demand for early diagnosis of the diseases is also increasing. Also, the pressure on the healthcare system is increasing with the growing population. The demand for care, services, and technologies is rising to prevent and treat chronic diseases at old age. Therefore, the demand for advanced medical devices for the diagnosis of cancer is rising in the healthcare system worldwide.
Surge in Alcohol Consumption and Smoking is expected to drive the market's growth rate
The epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone, and so represents a severe public health issue that warrants further investigation. For instance, In June 2018, according to the Cancer Treatment Centers of America, 20% of American adults, nearly 38 million people, are smokers. Also, in 2010, according to the study on “Alcohol and tobacco use about gastric cancer: a prospective study of men in Shanghai, China” it was found that after accounting for alcohol consumption and other variables, every smoker had a statistically significant higher incidence of stomach cancer than non-smokers. The above instances show the relation between smoking and alcohol consumption as a risk factor for gastric cancer. Thus, the rise in alcohol consumption and surge in smoking is propelling the market growth.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2022 to 2029
|
Base Year
|
2021
|
Historic Years
|
2020(Customizable to 2014 - 2019)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Product Type (Instruments, Reagents & Consumables, Services), Diagnostics Type (Gastric (Pre) Cancer Screening Tests/Physical Exam, Confirmatory Tests), Age Group (Adult, Pediatric and Geriatrics), Disease Type (Intestinal Or Diffuse Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor [GIST], Gastric Lymphoma and Others), Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Gender (Male and Female), Sample Type (Blood, Tissue, Urine, and Stool), End Users (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics and Others), Distribution Channel (Direct Tenders and Retail Sales)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
Market Players Covered
|
General Electric (U.S.), Abbott (U.S.), Hologic Inc. (U.S.), Agilent Technologies Inc.(U.S.), F. Hoffmann-La Roche Ltd (Switzerland), FUJIFILM Corporation (Japan), Danaher (U.S.), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (U.S.), Siemens Healthcare GmbH (Germany), BD (U.S.), bioMérieux (France), Bio-Rad Laboratories Inc. (U.S.), Cancer Diagnostics Inc. (U.S.), Vela Diagnostics (Singapore), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (U.S.), Bio SB (U.S.), Biocartis (Belgium), Exact Science (U.S.)
|
Data Points Covered in Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global gastric cancer diagnostics market is categorized into nine notable segments which are based on the product type, diagnostics type, age group, type, stage, gender, sample type, end users and distribution channel.
The reagents and consumables segment is expected to dominate the gastric cancer diagnostics market growing with the highest CAGR of 8.0%
In 2021, the reagents and consumables segment is expected to dominate the gastric cancer diagnostics market growing with the highest CAGR of 8.0% in the forecast period of 2021 to 2028 because number of top players developing kits for gastric cancer, and wider range of kits products available in the market. Moreover, IVD players are also focusing on the development of more advanced kits.
The stool segment is expected to dominate the gastric cancer diagnostics market growing with the highest CAGR of 8.6%
In 2021, the stool segment is expected to dominate the gastric cancer diagnostics market growing with the highest CAGR of 8.6% in the forecast period of 2021 to 2028 because most of the diagnostics performed from stool sample as well as availability of stool diagnostic products with companies.
Major Players
Data Bridge Market Research recognizes the following companies as the major gastric cancer diagnostics market players in gastric cancer diagnostics market are General Electric (U.S.), Abbott (U.S.), Hologic Inc. (U.S.), Agilent Technologies Inc.(U.S.), F. Hoffmann-La Roche Ltd (Switzerland), FUJIFILM Corporation (Japan), Danaher (U.S.), DiaSorin S.P.A. (Italy), Myriad Genetics Inc. (U.S.), Siemens Healthcare GmbH (Germany), BD (U.S.), bioMérieux (France), Bio-Rad Laboratories Inc. (U.S.), Cancer Diagnostics Inc. (U.S.), Vela Diagnostics (Singapore), AMOY Diagnostics CO. LTD. (China), Quidel Corporation (U.S.), Bio SB (U.S.), Biocartis (Belgium), Exact Science (U.S.)
Market Development
Regional Analysis
Geographically, the countries covered in the gastric cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in gastric cancer diagnostics market during the forecast period
North America dominated the gastric cancer diagnostics market owing to the increasing number of geriatric population and the development of advanced technology. North America will continue to dominate the gastric cancer diagnostics market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
Asia-Pacific is estimated to be the fastest-growing region in gastric cancer diagnostics market
Asia-Pacific is expected to grow during the forecast period due to the increasing research and development for the gastric cancer diagnostics in this region. In addition, the growing presence of major market players are expected to propel the market's growth rate in this region.
COVID-19 Impact Analysis
The outbreak of COVID-19 pandemic, led to significant negative effects on healthcare sector. The gastric cancer diagnostics market was largely impacted due to severe government regulations, statewide lockdowns, increased infection rates, decreased patient visits to hospitals and clinics, and a shortage of medical professionals and healthcare workers.
For more detailed information about the gastric cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/reports/global-gastric-cancer-diagnostics-market
Global Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Asia-Pacific Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Middle East and Africa Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028
North America Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028
Europe Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028